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Abstract
Background: In order to test the hypothesis that inhaled nitric oxide (NO) reverses the pulmonary
hypertension induced by αα-diaspirin crosslinked hemoglobin (ααHb), were studied anesthetized pigs
that were administered with a total dose of 200 mg/kg of 10% ααHb. Inhaled NO (5 ppm) was
administered for 10 min, and then discontinued for 10 min. This cycle was then repeated with 10 ppm
inhaled NO.
Results: ααHb caused pulmonary arterial pressure (PAP) to increase from 27 ± 1.7 to 40 ± 3.0 mmHg
(P<0.05) and dynamic lung compliance to decrease from 29± 1.5 to 23± 1.6 ml/cmH2O (P < 0.05).
After both doses of inhaled NO, but particularly 10 ppm, PAP was reduced (P < 0.05) and lung
compliance increased (P < 0.05) from the ααHb levels. When inhaled NO was discontinued PAP again
increased and lung compliance decreased to levels significantly different from baseline (P < 0.05).
Conclusion: We conclude that cell-free hemoglobin-induced pulmonary hypertension and decreased
lung compliance can be selectively counteracted by inhaled NO.
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Introduction
Cell-free hemoglobin oxygen-carrying solutions are now
undergoing clinical trials. Such solutions may overcome the
limitations of homologous blood transfusion. Preservation
of cardiovascular function and oxygen transport has been
demonstrated after partial and complete exchange transfu-
sion with cell-free hemoglobin solutions [1–4]. Hemoglobin
solutions may have potential particularly as a resuscitative
fluid due to their pharmacological actions, which cause
increases in arterial pressure and blood flow even in small
doses [5,6].
However, it has been demonstrated that pulmonary hyper-
tension, leading to hypoxemia and hemodynamic instability,
may offset the benefits of cell-free hemoglobin blood sub-
stitutes [7–11]. The main mechanism by which these solu-
tions produce vasoconstriction is by binding and
inactivating nitric oxide (NO) [12–14], a key mediator
responsible for the physiological regulation of the vasodila-
tory tone.
Selective pulmonary vasodilation with inhaled NO adminis-
tration has been widely demonstrated in animal models and
in patients with pulmonary hypertension [15–17].Selective
pulmonary vasodilation occurs because inhaled NO is
rapidly inactivated by hemoglobin as it enters the circula-
tion; hemoglobin's affinity for NO is many thousand times
greater than for either oxygen or carbon monoxide [18–20].
It has also been shown that inhaled NO can attenuate bron-
choconstriction [21,22]. We are unaware of any evaluation
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and airway resistance.
We hypothesized that inhaled NO will selectively counter-
act the pulmonary hypertension induced by cell-free hemo-
globin blood substitutes. To test our hypothesis we
performed experiments in pigs administered with inhaled
NO after αα-diaspirin crosslinked hemoglobin (ααHb) infu-
sion. We also evaluated the effects of ααHb on dynamic
lung compliance and airway resistance, and the response
of these parameters to inhaled NO. Our preliminary results
demonstrated that cell-free hemoglobin-induced pulmonary
hypertension and decreased lung compliance can be
selectively counteracted by inhaled NO.
Materials and methods
The study was performed using five immature female York-
shire pigs, weighing 28.6 ± 0.6kg. The experimental proto-
col was reviewed and approved by the Animal Care and
Use Committee of the University of Texas Medical Branch
at Galveston, with adherence to National Institutes of
Health guidelines for the care and use of laboratory animals
(DDHS Publication, NIH, 86–23).
Animal preparation
The animals were fasted for 12 h before the study, with free
access to water. Anesthesia was induced with an intramus-
clar injection of ketamine hydrochloride (10 mg/kg), atro-
pine sulfate (0.04 mg/kg) and by inhalation of 5%
isoflurane. After endotracheal intubation, an intravenous
bolus of pancuronium bromide (0.08 mg/kg) and fentanyl
(30 µ g/kg) was administered. Anesthesia was then main-
tained with a continuous infusion of fentanyl (5 µ g/kg/min).
The volume and rate of the ventilator (Servo 900C, Sie-
mens-Elema AB, Solna, Sweden) were set to maintain arte-
rial CO2 tension at 35–40 mmHg, using the assist control
mode an I:E ratio maintained at 1:3. An inspired oxygen
fraction of 0.95 was used throughout the experiment, which
maintained an arterial oxygen tension of between 400 and
450 mmHg and an arterial oxygen saturation > 97%. Core
body temperature was maintained with a heating pad and
warming lights.
Polyethylene cannulas were inserted into the abdominal
aorta through the right femoral artery for continuous record-
ing of aortic blood pressure, heart rate and arterial blood
sampling for blood gas analysis, and into the inferior vena
cava through the right femoral vein for infusion of anesthetic
agents, αα Hb and maintenance fluid (lactated Ringer's
solution; 5 ml/kg/h). A 7.5-F flow-directed thermodiultion
fiberoptic pulmonary artery catheter (Opticath P7110,
Abbott Critical Care Systems, Mountain View, CA, USA)
was guided by pressure monitoring and wave tracings
through the right external jugular vein and the tip placed into
the pulmonary artery. This catheter was used for measure-
ment of pulmonary arterial pressure, continuous mixed
venous oxyhemoglobin saturation (SvO2), and cardiac out-
put by thermodilution (Oximetric 3 SO2/CO computer,
Abbott, Chicago, IL, USA). Each catheter was connected
to a pressures transducer (Transpac Disposable Trans-
ducer, Abbott) and to a Biopac Data Acquistion System
(Model MP100, Biopac Systems, Goleta, CA, USA) for
continuous recording of heart rate, systemic and pulmonary
arterial pressures, and waveforms. Blood samples and
methemoglobin levels were analyzed by a pH/Blood Gas
Analyzer 1303 and CO-Oximeter 482 (Instrumentation
Laboratory, Lexington, MA, USA).
The ααHb used in this study was derived from outdated
human blood and prepared according to previously pub-
lished methods [10,23]. ααHb is crosslinked between the
alpha subunits at α-Lys99 and bis-(3,5-dibromosalicyl)
fumarate. The ααHb solution had a hemoglobin content of
10 g/dl, an osmolality of 300 mOsm/l, an oncotic pressure
of 42 mmHg, a P50 (PaO2 at which 50% of hemoglobin is
saturated with oxygen) of 29 mmHg and had ≤ 4% of its
hemoglobin in the form of methemoglobin. It was provided
through a Cooperative Research & Development Agree-
ment with the Blood Research Detachment of the Walter
Reed Army Institute of Research.
The NO (800 ppm in nitrogen) was titrated using a 3500HL
blender (Sechrist Industries, Anaheim, CA, USA) with com-
pressed air as the mixing gas. The diluted gas was then
connected to the air side of the blender on the Servo 900C.
The gas was titrated to achieve concentrations of 5 ppm
and 10 ppm with 95% oxygen. The inhaled NO concentra-
tion was confirmed using an electrochemical sensor (Pul-
monox II NO-NO2 analyzer, Pulmonox Medical Corp,
Tofield, Alberta, Canada).
Experimental protocol
After a 30-min period of stabilization following surgical
preparation, baseline data were obtained. αα Hb was
administered in cumulative doses of 0.1, 0.5, 1.0 and 2.0
ml/kg, in 5-min intervals to a total dose of 2ml/kg (=200
mg/kg ααHb); the data were collected 10 min after the final
ααHb infusion. Inhaled NO, in concentration of 5 ppm, was
then administered for 10 min and data were recorded. The
inhaled NO was discontinued for 10 min, after which data
were again recorded. This cycle was repeated with 10 ppm
inhaled NO. After the final measurements the animals were
killed with an anesthetic overdose and saturated potassium
chloride solution.
Experimental measurements
Mean arterial pressure (MAP), mean pulmonary arterial
pressure (PAP) central venous pressure (CVP), heart rate
and SvO2 were continuously monitored; pulmonary artery
occlusion pressure (PAOP) was measured in 5 min inter-
Available online http://ccforum.com/content/1/3/111vals. Cardiac output was determined by the thermodilution
technique and is presented as cardiac index determined
using calculated body surface area. Systemic and pulmo-
nary vascular resistance indices (SVRI and PVRI, respec-
tively) were calculated using standard formulae.
All measurements relating to lung volume, pressures, air-
way resistance and dynamic lung compliance were contin-
uously monitored and recorded with a Ventrak Model 1500
(Novametrix Medical Systems, Wallingford, CT, USA). This
system determines dynamic lung compliance by measuring
the peak pressure at zero flow [minus any positive end-
expiratory pressure (PEEP)] and tidal volume delivered and
then calculating the compliance using the following
formula:
Lung compliance (ml/cm H2O) = change in volume/(peak
pressure-PEEP).
For airway resistance, the system measures the pressure at
the end of inspiration and the peak expiratory flow, then
applies the following formula:
Airway resistance (cmH2O/I/s) = alveolar pressure/(peak
expiratory flow/60).
End expiratory pressure (minus PEEP) is used as the alve-
olar pressure and is measured at the proximal end of the
endotracheal tube.
Firstly, data were recorded at baseline (BL) and 10 min
after 200 mg/kg ααHb infusion (ααHb). Data were then
recorded at the end of each of the following 10-min peri-
ods: inhaled NO at 5 ppm (NO 5 ppm), NO discontinued
(OFF), inhaled NO at 10 ppm (NO 10 ppm), NO discontin-
ued (OFF).
Statistical analysis
Data were analyzed using analysis of variance for a single-
factor experiment with repeated measures on time points
(baseline, ααHb, NO 5 ppm, OFF, NO 10 ppm, OFF).
Fisher's least significant difference procedure was used for
multiple comparisons, with Bonferroni adjustment for
number of comparisons. For all tests P < 0.05 was consid-
ered significant.
Results
Infusion of ααHb caused a significant increase of approxi-
mately 50% in PAP (Fig 1) while significant decreases in
SvO2 and heart rate were observed (14% and 17%
respectively) (Table 1). Increases in MAP, CVP, PAOP,
PVRI and SVRI were observed after ααHb while cardiac
index was slightly reduced; none of these changes were
statistically significant (Table 1). Dynamic lung compliance
showed a 22% reduction (P < 0.05) while airway resist-
ance increased 14% (not significant) after ααHb infusion
(Fig 2). Inhaled NO at both concentrations, but particularly
10 ppm, ameliorated the ααHb-induced changes in PAP
and lung compliance (Figs 1 and 2), while only modest
changes in the other variables were observed (Fig 2,Table
1). After inhaled NO 5 ppm, PAP was significantly reduced
(P < 0.05) from ααHb levels, but was slightly higher than
baseline (not significant). When inhaled NO was discontin-
ued, PAP increased to values higher than baseline (P <
0.05), but not significantly different than levels during
inhaled NO 5 ppm. Inhaled NO 10 ppm reduced PAP (P <
0.05) to baseline values, but after NO discontinuation PAP
returned to values that were significantly higher than base-
line (Fig 1).
Lung compliance, which was markedly reduced by ααHb,
showed a modest rise with inhaled NO 5 ppm, while a sub-
stantial increase (P < 0.05) was observed after inhaled NO
10 ppm (Fig 2). When inhaled NO was discontinued, lung
Table 1
Hemodynamic data (mean ± SEM)
Variable Baseline ααHb NO 5 ppm OFF NO 10 ppm OFF
MAP (mmHg) 97 ± 3.9 119 ± 7.0 117 ± 9.7 120 ± 10.4 117 ± 7.7 116 ± 10.2
CVP (mmHg) 4.0 ± 1.5 6.5 ± 1.3 4.8 ± 1.4 4.9 ± 0.9 4.5 ± 1.9 4.8 ± 1.7
PAOP (mmHg) 9.6 ± 1.9 12.6 ± 1.7 11.2 ± 1.9 10.6 ± 1.5 10.4 ± 1.3 12.4 ± 2.5
HR (beats/min) 106 ± 3.9 88 ± 4.5 90 ± 7.6 92 ± 6.7 91 ± 5.6 95 ± 5.8
Cl (ml/min/m2) 4.7 ± 0.4 4.2 ± 0.1 3.5 ± 0.4 3.4 ± 0.5 3.7 ± 0.5 3.2 ± 0.5
SVRI (dyn s/
cm5m2)
1603 ± 100 2152 ± 147 2952 ± 492 2952 ± 570 2655 ± 348 3286 ± 559
PVRI(dyn s/cm5m2) 291 ± 67 513 ± 92 485 ± 114 657 ± 139 396 ± 73 663 ± 146
SvO2(%) 93 ± 0.1 80 ± 4.3 78 ± 8.4 78 ± 7.8 77 ± 5.7 77 ± 7.9
ααHb: αα-crosslinked hemoglobin 200 mg/kg; NO 5ppm = 5ppm inhaled nitric oxide; NO 10 ppm = 10 ppm inhaled nitric oxide; OFF = nitric 
oxide discontinued; MAP = mean arterial pressure; CVP = central venous pressure; PAOP = pulmonary artery occlusion pressure; HR = heart rate; 
CI = cardiac index; SVRI = systemic vascular resistance index; PVRI = pulmonary vasclar resistance index; SvO2 = mixed venous oxygen saturation 
*P<0.05 compared to baseline.Page 3 of 6
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0.05). On the other hand, airway resistance showed no sig-
nificant changes throughout the experiment. The other var-
iables showed no significant changes after either NO
inhalation or discontinuation, except for cardiac index,
which was significantly lower than baseline only at the final
measurement and for both SVRI and PVRI, which were
higher than baseline (P < 0.05) when inhaled NO was dis-
continued (Table 1).
Discussion
We demonstrated that inhaled NO can selectively reverse
the pulmonary hypertension and decreased lung compli-
ance induced by cell-free hemoglobin. This suggests that
its is possible to effectively control potentially deleterious
side-effects associated with the clinical use of cell-free
hemoglobin-based blood substitutes.
Pulmonary hypertension after cell-free hemoglobin solu-
tions has also been reported by other investigators using
animal models of exchange transfusion, hemodilutin, sepsis
and hemorrhagic shock [7–11]. In a previous study of hem-
orrhaged pigs we showed that, although arterial pressure
and brain blood flow were restored to prehemorrhage val-
ues after small volume (4 ml/kg) infusion of ααHb, a two-
fold increase in pulmonary pressure and a four-fold
increase in pulmonary vascular resistance were undesirable
side-effects [7]. In a subsequent similar study in which
ααHb was used concomitantly with systemic vasodilators,
pulmonary pressure transistenly equalized systemic
pressures, leading to marked hemodynamic instability in
two out of six pigs [8].
Cell-free hemoglobin produces its vasopressor effect pri-
marily by binding and scavenging NO [12–14], although
release of endothelin and other vasoconstrictors may play a
role. When hemoglobin is within the red blood cells, NO is
removed as it dissolves into the plasma and ultimately inter-
acts with hemoglobin. When hemoglobin is free in solution,
NO is inactivated to a greater extent, thereby causing vaso-
constriction [18,19].
These properties of cell-free hemoglobin have suggested
its use as treatment for conditions associated with exces-
sive NO production, such as sepsis-induced hypotension
and low systemic vascular resistance [24,25]. However,
cell-free hemoglobin caused a significant exacerbation of
Figure 1
Mean pulmonary arterial pressure. BL = basline; ααHb = αα-
crosslinked hemoglobin 200 mg/kg; NO 5 ppm = 5 ppm inhaled nitric 
oxide; OFF = nitric oxide discontinued; NO 10 ppm = 10 ppm inhaled 
nitric oxide. aP < 0.05 compared to baseline; bP < 0.05 compared to 
ααHb; cP < 0.05 compared to OFF.
Figure 2
(a) Lung compliance and (b) airway resistance. BL = baseline; ααHb = 
αα-crosslinked hemoglobin 200 mg/kg; NO 5 ppm = 5 ppm inhaled 
nitric oxide; NO 10 ppm = 10 ppm inhaled nitric oxide; OFF = nitric 
oxide discontinued. aP < 0.05 compared to baseline; bP #60; 0.05 
compared to ααHb.
Available online http://ccforum.com/content/1/3/111endotoxin-induced pulmonary hypertension and arterial
hypoxemia in endotoxemic pigs [9]. Hypoxemia, respiratory
acidosis and ventilation-perfusion abnormalities were
observed in a canine model of bacteremia after cell-free
hemoglobin infusion [26].
We have demonstrated in this study that dynamic lung
compliance is significantly decreased by cell-free hemo-
globin, a finding that may explain in part some of the venti-
latory problems described in septic animal models [9,26].
Inhaled NO, particularly at a dose of 10 ppm, completely
restored lung compliance. This benefit was observed with-
out significant changes occurring in airway resistance,
although a bronchodilatory effect has been previously
ascribed to inhaled NO [21,22].
The mechanism involved in hemoglobin-induced decreases
in lung compliance is not known. Previous studies have
documented that inhaled NO has a predominant
vasodilating effect on the pulmonary venous vasculature,
thereby lowering the pulmonary capillary pressure and
reducing fluid filtration in the lung [27]. It has been shown
that the inhibition of NO production by L-nitro arginine
methyl ester (L-NAME) caused a higher contraction in pul-
monary veins than in pulmonary arteries in isolated vessels
from septic sheep [28]. Therefore, it is tempting to specu-
late that inhibition of NO by cell-free hemoglobin with sub-
sequent venoconstriction and increased capillary pressure
may increase extravascular lung water, contributing to the
decreased lung compliance.
Surprisingly, human studies evaluating the safety of hemo-
globin-based blood substitutes do not appear to directly
address the potentially dangerous side-effects of pulmo-
nary hypertension and decreased lung compliance. One
study, presented as an abstract [29], in which a very small
dose of cell-free hemoglobin (50 mg/kg) was infused to 11
anesthetized patients showed that mean PAP increased
from 21 to 27 mmHg, measured 30 min after infusion. This
finding illustrates the potential for adverse effects in
humans, particularly in patients with pre-existing diseases
and limited cardiac and pulmonary function. On the other
hand, hundreds of patients have been tested and safety is
claimed with most hemoglobin-based blood substitutes.
Unfortunately only limited data are available in the peer-
reviewed literature, making it difficult to correlate the con-
cerns raised in this study suggests that it will be an effec-
tive approach to selectively counteract the undesirable
side-effects of hemoglobin solutions in the pulmonary
circulation.
Although caution should be exercised when drawing clini-
cal implications from animal studies, the pig is usually con-
sidered an appropriate animal model because of its
anatomical and physiological similarities to humans, partic-
ularly regarding the heart and lungs. Prospective clinical
studies addressing pulmonary pressures and right ventricle
performance are needed; complete hemodynamic evalua-
tion should be performed in the ongoing blood substitute
trials, as this is the only means to determine whether con-
cerns raised by animal studies are clinically relevant. The
limitations of our study, which include a small sample size,
no control group and short experimental period, resulted
from a small supply of the hemoglobin. However, were
clearly demonstrated the potential for inhaled NO to modu-
late the increased PAP and decreased lung compliance
without major effects in the systemic circulation.
We conclude that inhaled No selectively reverses pulmo-
nary hypertension and decreased lung compliance induced
by cell-free hemoglobin blood substitutes.
Acknowledgements
The authors thank Tatsuo Uchida for statistical analysis and the US Army
for providing the αα -hemoglobin used in this study. The study was per-
formed at the Department of Anesthesiology, University of Texas Medi-
cal Branch, Galveston, TX, USA. Luiz F Poli de Figueiredo was a Visiting
Assistant Professor at University of Texas Medical Branch during these
experiments, with a sponsorship by Fundação de Apoio a Pesquisa
Estado de São Paulo, FAPESP-Brazil, Grant 93/3796-5.
References
1. Dietz NM, Joyner MJ, Warner MA: Blood substitutes: fluids,
drugs, or miracle solutions? Anesth Analg 1996, 82:390-405.
2. Spahn DR, Leone BJ, Reves JG, Pasch T: Cardiovascular and
coronary physiology of acute isovolemic hemodultion: a
review of nonoxygen-carrying and oxygen-carrying solutions.
Anesth Analg 1994, 78:1000-1021.
3. Hughes GS, Antal EJ, Locker PK, Francom SF, Adams WJ, Jacobs
EE: Physiology and pharmacokinetics of a novel hemoglobin-
based oxygen carrier in humans. Crit Care Med 1996, 24:756-
764.
4. Vlahakes GJ, Lee R, Jacobs EE Jr, Laraya Pj, Austen WG: Hemo-
dynamic effects and oxygen transport properties of a new
blood substitute in a model of massive blood replacement. J
Thorac Cardiovasc Surg 1990, 100:379-388.
5. Cohn SM, Farell TJ: Diaspirin cross-linked hemoglobin resusci-
tation of hemorrhage: comparison of a blood substitute with
hypertonic saline and isotonic saline. J Trauma 1995, 39:210-
216.
6. Schultz SC, Powell CC, Burris DG, Nguyen H, Jaffin J, Malcom
DS: The efficacy of diaspirin crosslinked hemoglobin solu-
tions resuscitation in a model of uncontrolled hemorrhage. J
Trauma 1995, 37:408-412.
7. Poli de Figueiredo LF, Mathru M, Solanki D, Macdonald VM, Hess
JR, Kramer GC: Pulmonary hypertension and systemic vaso-
constriction may offset the benefits of a cellular hemoglobin
blood substitutes. J Trauma  1997, 42:847-854.
8. Poli de Figueiredo LF, Mathru M, Elgjo GL, Rocha de Silva M,
Kramer GC: Hypertonic acetate αα -hemoglobin for small vol-
ume resuscitation of hemorrhagic shock. Art Cells Blood Subs
Immob Biotech 1997, 25:61-73.
9. Aranow JS, Wang H, Zhuang J, Fink MP: Effect of human hemo-
globin on systemic and regional hemodynamics in a porcine
model of endotoxemic shock.  Crit Care Med 1996, 24:807-
814.
10. Hess JR, Macdonald VW, Brinkley WW: Systemic and pulmo-
nary hypertension after resuscitation with cell-free hemo-
globin.  J Appl Physiol 1993, 74:1769-1778.
11. Lee R, Neya K, Svizzero TA, Vlahakes GJ: Limitations of the effi-
cacy of hemoglobin-based oxygen-carrying solutions.  J Appl
Physiol 1995, 79:236-242.Page 5 of 6
(page number not for citation purposes)
Critical Care   Vol 1 No 3    Figueiredo et al.12. Katusic ZS, Lee HC, Clambey ET: Crosslinked hemoglobin
inhibits endothelium-dependent relaxains in isolated canine
arteries. Gen Pharmacol 1996, 27:239-244.
13. Rioux F, Petitclerc E, Audet R, Drapeau G, Fielding RM, Marceau
F: Recombinant human hemoglobin inhibits both constitute
and cytokine-induced nitric oxide-mediated relaxation of rab-
bit isolated aortic rings. J Cardiovasc Pharmacol 1994, 24:229-
237.
14. Poli de Figueiredo LF, Williams N, Mathru M, Lee MN, Nelson SH:
Acellular hemoglobin blood substitutes impair nitroprusside-
induced relaxation of rat aorta. Anesthesiology 1996, 85:A571.
15. Frostell C, Fratacci MD, Wain JC, Jones JC, Zapol WM: Inhaled
nitric oxide: a selective pulmonary vasodilator reversing
hypoxic pulmonary vasoconstiction.  Circulation 1991,
83:2038-2047.
16. Rossaint R, Falke K, Lopez F, Slama K, Pison U, Zapol WM:
Inhaled nitric oxide for the adult respiratory distress
syndrome. N Engl J Med 1993, 328:399-405.
17. Frostell CG, Zapol WM: Inhaled nitric oxide, clinical rationale
and applications. Adv Pharmacol 1995, 34:439-456.
18. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology,
patho-physiology, and pharmacology. Pharmacol Rev 1991,
43:109-142.
19. Moncada S, Higgis EA: Molecular mechanisms and therapeutic
strategies related to nitric oxide.  FASEB J 1995, 9:1319-1330.
20. Rimar S, Gillis N: Selective pulmonary vasodilation by inhaled
nitric oxide is due to hemoglobin inactivation. Circulation 1993,
88:2884-2887.
21. Kacmarek RM, Ripple R, Cockrill BA, Block KJ, Zapol WM, John-
son DC: Inhaled nitric oxide. A bronchodilator in mild asthmat-
ics with methacoline-induced bronchospasm. Am J Resp Crit
Care Med 1996, 153:128-135.
22. Dupuy PM, Shore SA, Drazen JM, Frostell C, Hill WA, Zapol WM:
Bronchodilator action of inhaled nitric oxide in guinea pigs.  J
Clin Invest 1992, 90:421-428.
23. Winslow RM, Chapman K, Everse J: Pilot scale production of
pyrogen-free modified human hemoglobin for research.  Bio-
mater Artif Cells Immob Biotech 1992, 20:415-421.
24. Mourelatos MG, Enzer N, Ferguson JL, Rypins EB, Burthop KE,
Law WR: The effects of diaspirin cross-linked hemoglobin in
sepsis. Shock 1996, 5:141-148.
25. Ulatowski JA, Nishikawa T, Matheson-Urbaitis B, Bucci E, Trays-
man RJ, Koehler RC: Regional blood flow alterations after
bovine fumaryl ββ-crosslinked hemoglobin transfusion and
nitric oxide synthase inhibition. Crit Care Med 1996, 24:558-
565.
26. Crowley JP, Metzger J, Gray A, Pivacek LE, Cassidy G, Valeri CR:
Infusion of stroma-free cross-linked hemoglobin during acute
gram-negative bacteremia. Crit Shock 1993, 41:144-149.
27. Benzing A, Geiger K: Inhaled nitric oxide lowers pulmonary cap-
illary pressure and changes longitudinal distribution of pulmo-
nary vascular resistance in patients with acute lung injury. Acta
Anaesthesiol Scand 1994, 38:640-645.
28. Nelson SH, Ehardt JS, Lingnau W, Herndon DN, Traber D: Differ-
ential effects of prolonged septicemia on isolated pulmonary
arteries and veins from sheep. Shock 1996, 5:440-445.
29. Garrioch M, Larbuisson R, Brichant JF, Daily E, Przybelski R: The
hemodynamic effects of diaspirin cross-linked hemoglobin
(DCLHb) in the operative setting. Crit Care Med 1996, 24:A39.
